Long-term data on the infl uence of cigarette smoking, especially cessation, on the risk of Crohn ' s disease (CD) and ulcerative colitis (UC) are limited.
INTRODUCTION
Th e etiologies of Crohn ' s disease (CD) and ulcerative colitis (UC), the two main forms of infl ammatory bowel disease (IBD), remain unknown, but are thought to be multifactorial, with both genetic and environmental infl uences ( 1, 2 ) . Multiple studies have reported signifi cant associations between cigarette smoking and the risk of IBD, although the eff ect of smoking appears to diff er between CD and UC ( 3, 4 ) . In previous analyses, current smoking has been associated with a higher risk of CD but a lower risk of UC. Moreover, smoking cessation may increase UC risk ( 3 -11 ) . Nonetheless, the majority of previous studies that assessed the relationship between smoking and IBD were retrospective, case -control studies limited by recall and selection biases ( 5 -10 ) . Th e few prospective cohort studies that have examined smoking included only a small number of cases and did not collect updated smoking status exposure data over long-term follow-up ( 12, 13 ) .
We therefore performed a post-hoc analysis of smoking information, obtained before diagnosis, on the risk of IBD among 229,111 women enrolled in two large ongoing, prospective cohort studies. Over 32 years of follow-up, we documented 736 incident cases of CD and UC. Moreover, in both cohorts, smoking data was updated biennially, thereby minimizing misclassification of smoking exposure and allowing a detailed assessment of the infl uence of smoking cessation on the risk of incident CD and UC.
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METHODS
Study cohorts
Th e Nurses ' Health Study (NHS) and Nurses ' Health Study II (NHS II) are two large prospective cohort studies. NHS was initiated in 1976, when 121,701 US female registered nurses, 30 -55 years of age, completed a mailed questionnaire, including a detailed assessment of past and current smoking history ( 14 -16 ) . NHS II was established in 1989 with a parallel cohort of 116, 671 US female registered nurses, 25 -42 years of age ( 17, 18 ) . Every 2 years, participants in both cohorts have been followed with similar biennial questionnaires. In both cohorts, follow-up has remained > 90 % . All aspects of this study were approved by the Partners ' HealthCare Institutional Review Board and Children ' s Hospital Boston Institutional Review Board.
Assessment of smoking exposure
On the 1976 baseline NHS questionnaire and the 1989 baseline NHS II questionnaire, past and current smokers were asked to indicate the average number of cigarettes they smoked per day, the age at which they began smoking, and, among past smokers, the age at which they stopped smoking. Biennially, participants have provided updated data on their smoking status and the number of cigarettes smoked in categories (1 -4, 5 -14, 15 -24, 25 -34, 35 -44, or ≥ 45 cigarettes per day). We assessed cumulative exposure to cigarette smoking according to pack-years, defi ned as having smoked one pack or 20 cigarettes / day over an entire year. Th e number of pack years was calculated by multiplying the number of packs smoked per day by the number of years during which that amount was smoked. For example, if one smoked 2 packs / day for 6 months, this would equal 1 pack year. All categories were created before data analysis ( a priori ).
Assessment of other exposures
Beginning with the 1976 questionnaire for NHS and the 1989 questionnaire for NHS II, women provided information for height, weight, oral contraceptive use, and postmenopausal hormone use that was updated with each biennial questionnaire. In a previous validation study, 184 women were weighed by technicians 6 -12 months aft er completion of mailed questionnaire and reported weights were highly correlated with measured weights ( r = 0.96) ( 19 ) . Body-mass index was calculated as the weight in kilograms divided by the square of the height in meters.
Identifi cation of CD and UC
We previously have detailed our methods for confi rming selfreported cases of CD and UC ( 20 ) . Since 1976 in NHS and 1989 in NHS II, participants have reported diagnoses of UC or CD through an open-ended response on biennial questionnaires. In NHS, we specifi cally have queried participants about diagnoses of UC since 1982 and CD since 1992. In NHS II, we specifi cally have queried participants about diagnoses of both UC and CD since 1993. Participants were asked to indicate the time period in which they were diagnosed. When a diagnosis of CD or UC was reported on any biennial questionnaire, we mailed the participant a supplemental IBD survey, which included a more detailed description of CD and UC, as well as a questionnaire requesting detailed information regarding symptoms, diagnostic testing, and treatments, and permission to examine related medical records. If permission was granted, medical records were independently reviewed by two gastroenterologists, blinded to all exposure data. Reviewers extracted data regarding clinical presentation and endoscopic, histopathological, radiological, and surgical specimen fi ndings. Cases of CD and UC with date of diagnosis (date of initial endoscopic, histopathological, radiological, or surgical specimen evidence of CD or UC) were confi rmed according to strict diagnostic criteria for CD and UC (see Supplementary Material online) ( 21 -25 ) . Disagreements were resolved through consensus.
We have previously confi rmed that the baseline characteristics (smoking status, body-mass index, oral contraceptive use, and postmenopausal hormone use) of participants for whom we were able to obtain complete medical records were similar to those of participants for whom we were unable to obtain suffi cient records ( 20 ) . Participants for whom we did not confi rm CD and UC were included in the analyses as non-cases.
Population for analysis
We excluded participants who did not provide smoking information on the baseline questionnaires in 1976 for NHS and in 1989 for NHS II. We also excluded women who reported a history of IBD or cancer (except non-melanoma skin cancer) before study baseline and those who did not provide information on the baseline questionnaires for height, oral contraceptive use, or postmenopausal hormone use. Aft er these exclusions, 115,290 women in NHS and 113,821 women in NHS II were eligible for analysis.
Statistical analyses
In the primary analysis, we calculated incidence rates of CD or UC for participants in each category of biennially updated smoking status by dividing the number of incident cases by the number of person-years of follow-up. Participants accrued follow-up time beginning on the date of the return of the baseline questionnaire and ending on the date of diagnosis of CD or UC, date of death, or at the end of the follow-up period, June 30, 2008 for NHS and June 30, 2007 for NHS II, whichever came fi rst. We calculated hazard ratios (HRs) by dividing the incidence rate in each exposure category by the incidence rate in the reference category. For smoking status, analyses compared current smokers and past smokers with the reference group, never smokers. We used Cox proportional hazards modeling to determine HRs and 95 % confi dence intervals (CIs) and to simultaneously adjust for other potential risk factors to estimate HRs and 95 % CIs. In our multivariate models, we adjusted for baseline body-mass index and biennially updated oral contraceptive use and postmenopausal hormone-replacement therapy, to account for changes in the use of these agents over follow-up. In secondary analyses, using a priori defi ned categories, we assessed the infl uence of smoking dose among current smokers, cumulative exposure to smoking cigarettes (pack years), and smoking cessation among past smokers. We performed a
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two-year lagged analysis for the examination of smoking cessation and UC. Linear tests for trend were calculated for cumulative exposure to smoking and smoking cessation models. We performed tests of heterogeneity for the associations in both NHS and NHS II using the Q statistic and observed no signifi cant heterogeneity (Q probability > 0.29). Th us, for all analyses, we combined data from both cohorts ( 26 ) . We evaluated the proportional hazards assumption by likelihood ratio tests comparing models with and without time-dependent variable-by-variable interaction terms. Statistical models satisfi ed the proportionality of hazards assumption. We used SAS soft ware (version 9.1) for all analyses. We considered two-sided P values < 0.05 to be statistically significant. Adjustments for multiple comparisons were not performed as our smoking exposure variables were selected on the basis of a priori hypotheses and consistent with previous analyses of smoking in the cohorts ( 15, 16, 18 ) .
RESULTS
Table 1a
and b presents baseline characteristics of the eligible women at enrollment in NHS in 1976 and NHS II in 1989. In NHS, 33 % of the nurses were current smokers, 23 % were past smokers, and 44 % never smoked. In NHS II, 14 % of the nurses were current smokers, 21 % were past smokers and 65 % never smoked. For both cohorts, smoking status was updated biennially. During the 5,428,403 person-years of follow-up, we identifi ed and confi rmed 336 incident cases of CD and 400 incident cases of UC through 2008 in NHS and 2007 in NHS II.
Smoking status and risk of CD and UC
We observed a signifi cantly higher risk of CD among the current and past cigarette smokers compared with never smokers ( Table 2 ) . Current smoking was associated with a multivariate HR of CD of 1.90 (95 % CI, 1.42 -2.53), whereas former smokers experienced a HR of 1.35 (95 % CI, 1.05 -1.73), aft er adjustment for other covariates. By contrast, current smoking was not signifi cantly associated with the risk of UC (HR, 0.86; 95 % CI, 0.61 -1.20), but former smokers experienced a signifi cant elevation in risk (HR, 1.56; 95 % CI, 1.26 -1.93). Of note, among current smokers, we did not observe an association between number of cigarettes per day and the risk of either CD or UC.
Cumulative smoking dose and risk of CD and UC
We further examined the infl uence of cumulative smoking dose, measured by pack-years on the risk of CD and UC. Increasing pack-years was associated with an increasing risk of CD among all the participants (Ptrend < 0.0001), and this association remained signifi cant when we limited analyses to either current smokers (Ptrend < 0.0001) or past smokers (Ptrend = 0.0002) ( Table 3 ) . Given the heterogeneity in the eff ects of current and past smoking on the risk of UC, we examined cumulative pack-years among either current or past smokers ( Table 4 ) . Although there was no eff ect of cumulative pack-years on UC risk among current smokers, increasing pack-years conferred a signifi cant increase in risk among former smokers (Ptrend < 0.0001). Total N =115,290. a The body-mass index is the weight in kilograms divided by the square of the height in meters. The percentages of those postmenopausal women with never use, past use, and current use of hormones after menopause. The percentages of those postmenopausal women with never use, past use, and current use of hormones after menopause.
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Smoking cessation and risk of CD and UC
We examined the impact of cigarette smoking cessation on the risk of CD and UC. Compared with current smokers, smoking cessation appeared to attenuate the risk of CD over 20 years of follow-up (Ptrend = 0.03) ( Table 5 ). By contrast, there was an increase in risk of UC within 2 -5 years of smoking cessation (HR, 3.06; 95 % CI, 2.00 -4.67) that remained signifi cantly elevated even aft er increasing duration of smoking cessation (HR, 1.64; 95 % CI, 1.02 -2.64 for > 20 years of smoking cessation). We considered the possibility that the association between smoking cessation and UC refl ected cessation among aff ected, symptomatic subjects who
had not yet received a physician-defi ned diagnosis. We therefore repeated the analysis in which we excluded cases documented within the fi rst 2 years of each updated assessment of smoking status. Nonetheless, the results were not materially changed. Compared with current smokers, the multivariate HR for UC was 1.13(95 % CI, 0.74 -1.70) for ≤ 2 years, 2.12 (95 % CI, 1.37 -3.25) for 2.1 -5 years, and 2.10 (95 % CI, 1.33 -3.33) for 5.1 -10 years aft er smoking cessation.
DISCUSSION
We performed a post-hoc analysis of two large, prospective cohort studies of women in which smoking information was obtained before the diagnoses of CD and UC. We found that both current and former cigarette smoking was associated with a signifi cant increased risk of CD. Moreover, compared with never smokers, increasing pack-years among both current and past smokers conferred a signifi cant increase in the risk of CD. By contrast, current smoking was not associated with risk of UC, but cessation of cigarette smoking signifi cantly increased risk of UC within 2 -5 years of smoking cessation, with this eff ect persisting > 20 years aft er cessation. Our fi ndings for CD are consistent with observations from previous studies ( 3,4,6 -10 ) . One meta-analysis of seven retrospective case -control studies of smoking and CD reported a pooled odds ratio (OR) of 2.0 (95 % CI, 1.65 -2.47) among current smokers and 1.80 (95 % CI, 1.33 -2.51) among past smokers, when compared with never smokers ( 3 ). A separate meta-analysis observed slightly lower risks of CD with an overall OR of 1.76 (95 % CI, 1.40 -2.22) among current smokers and OR of 1.30 (95 % CI, 0.97 -1.76) among past smokers, when compared with never smokers ( 4 ) .
Th e apparent increased risk of UC among past smokers in the current study is consistent with fi ndings in most previous analyses ( 3 -8 ) , though not all ( 9, 10, 27 ) . Two previous meta-analyses reported a pooled OR of 1.64 (95 % CI, 1.36 -1.98) ( 3 ) and 1.79 (95 % CI, 1.37 -2.34) ( 4 ) for risk of UC among past smokers compared with never smokers. Of note, in the current study, increasing packyears conferred a signifi cant increase in the risk of UC only among former smokers. Although some studies have found a decreased risk of UC among current smokers ( 3 -7,9,10,28 ), other studies observed no statistically signifi cant diff erence in risk among current smokers compared with never smokers ( 8, 12, 13, 27, 29 ) , consistent with our fi ndings. Our fi nding of a relatively rapid increase in the risk of UC aft er smoking cessation was also observed in previous studies ( 5, 6, 11 ) . Although this association could be secondary to smoking cessation related to subclinical UC, the persistent elevation in risk beyond 20 years of cessation, strong dose -response (in pack-years) on risk among former smokers, and similar fi ndings when we excluded cases diagnosed within 2 years of smoking assessment support an association between smoking cessation and the development of UC.
Th e distinctly diff erent relationship between cigarette smoking and CD from that of smoking and UC underscores the complexity of the pathogenesis of these diseases ( 30, 31 ) . Whereas cigarette smoking consistently heralds an elevated risk of CD, one might speculate that it may suppress risk of UC in a genetically predisposed individual until smoking cessation, at which time the withdrawal of a potential protective eff ect of smoking may precipitate the onset of UC or unmask its symptoms ( 32 ) . Others have hypothesized that in a genetically susceptible individual, smoking status might infl uence disease phenotype, resulting clinically in the development of either CD or UC ( 33 ) .
Although nicotine has been considered a potential putative agent infl uencing CD and UC risk, cigarettes also are associated with the generation of free radicals and carbon monoxide which may have a mechanistic role ( 30 ) . Smoking may also aff ect the colonic mucus layer, modify cytokine production, modulate humoral and cellular immunity (innate and adaptive responses), reduce smooth muscle tone and activity, change gut permeability, and aff ect the microvasculature ( 30,31,34,35 ) . CI, confi dence interval. a Multivariate hazard ratios were adjusted for age, body-mass index ( < 22, 22 -24.9, 25 -29.9, or ≥ 30), oral contraceptive use (never use, past use, and current use), and postmenopausal hormone-replacement therapy (premenopausal women and postmenopausal women with never use, past use, or current use of hormone-replacement therapy).
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smoking and other risk factors were updated biennially, thus avoiding misclassifi cation during follow-up and permitting a detailed examination of the infl uence of smoking cessation that is not feaOur study has several strengths. Th e data collected before diagnosis avoids the potential recall and selection biases of previous retrospective, case -control studies. Our assessment of cigarette 
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sible in cohort studies with only baseline smoking information ( 12, 13 ) . Th e large number of participants and long-term follow-up facilitated ascertainment of a suffi cient number of incident cases of CD and UC for robust associations. Lastly, the confi rmation of cases of CD and UC by extensive medical record review by two blinded expert gastroenterologists and long-term follow-up over 32 years minimized misclassifi cation of outcomes based upon selfreport discharge coding. We acknowledge some limitations of our study. Our cohort is composed entirely of female health professionals and may not represent the overall US population. However, as shown in our previous analyses, our age-specifi c incidence of CD and UC were largely similar to rates from other US populations ( 20 ) . In addition, previous studies have shown that risk factors, including smoking, body-mass index, and dietary intake, among the participants in NHS and NHS II are consistent with those of the broader population of US women ( 36 -39 ) . Despite these fi ndings, we recognize that there may be potential unmeasured factors, uniquely associated with our cohort that may limit the generalizability of our fi ndings. Our study was also limited to a population aged between 25 -55 years at baseline enrollment. Th us, our fi ndings may not be generalizable to CD and UC among younger age groups.
To our knowledge, our study represents the largest cohort study with prospectively collected and updated smoking information, examining the associations between smoking and IBD. In summary, current and former cigarette smoking is associated with an increased risk of CD. By contrast, although current smoking was not associated with risk of UC, a history of former smoking, which persisted for several decades of cessation, was associated with an increased risk of UC. Further studies may clarify the mechanisms by which smoking and smoking cessation infl uence the risk of IBD.
